Allogene Therapeutics (ALLO) Enterprise Value: 2019-2025
Historic Enterprise Value for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $22.9 million.
- Allogene Therapeutics' Enterprise Value fell 92.20% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$822.7 million, marking a year-over-year increase of 16.41%. This contributed to the annual value of $154.1 million for FY2024, which is 68.50% up from last year.
- Latest data reveals that Allogene Therapeutics reported Enterprise Value of $22.9 million as of Q3 2025, which was up 188.38% from -$26.0 million recorded in Q2 2025.
- Allogene Therapeutics' 5-year Enterprise Value high stood at $4.3 billion for Q1 2021, and its period low was -$46.5 million during Q2 2024.
- In the last 3 years, Allogene Therapeutics' Enterprise Value had a median value of $91.5 million in 2023 and averaged $130.9 million.
- Data for Allogene Therapeutics' Enterprise Value shows a peak YoY increase of 346.25% (in 2024) and a maximum YoY decrease of 119.99% (in 2024) over the last 5 years.
- Allogene Therapeutics' Enterprise Value (Quarterly) stood at $1.7 billion in 2021, then crashed by 76.65% to $389.8 million in 2022, then tumbled by 76.53% to $91.5 million in 2023, then spiked by 68.50% to $154.1 million in 2024, then tumbled by 92.20% to $22.9 million in 2025.
- Its Enterprise Value stands at $22.9 million for Q3 2025, versus -$26.0 million for Q2 2025 and $37.2 million for Q1 2025.